open access

Vol 26, No 5 (2019)
REVIEW ARTICLE - CLINICAL CARDIOLOGY
Published online: 2018-04-25
Get Citation

Established and potential echocardiographic markers of embolism and their therapeutic implications in patients with ischemic stroke

Paulina E. Gąsiorek, Maciej Banach, Marek Maciejewski, Andrzej Głąbiński, Aleksandra Paduszyńska, Jacek Rysz, Agata Bielecka-Dąbrowa
DOI: 10.5603/CJ.a2018.0046
·
Pubmed: 29718528
·
Cardiol J 2019;26(5):438-450.

open access

Vol 26, No 5 (2019)
REVIEW ARTICLE - CLINICAL CARDIOLOGY
Published online: 2018-04-25

Abstract

Cardiogenic strokes comprised 11% of all strokes and 25% of ischemic strokes. An accurate identification
of the cause of stroke is necessary in order to prepare an adequate preventive strategy. In this review
the confirmed and potential causes of embolic strokes are presented, which can be detected in echocardiography in the context of present treatment guidelines and gaps in evidence. There remains a need for further studies assessing the meaning of potential cardiac sources of embolism and establishment of rules for optimal medical prevention (antiplatelet therapy [APT] vs. oral anticoagulation [OAC]) and
interventional procedures to reduce the incidence of ischemic strokes. Currently available data does not provide definitive evidence on the comparative benefits of OAC vs. APT in patients with cryptogenic stroke or embolic stroke of undetermined source. There is a lack of antithrombotic treatment scheme in the time between stroke and the completed diagnosis of potential sources of thromboembolism.

Abstract

Cardiogenic strokes comprised 11% of all strokes and 25% of ischemic strokes. An accurate identification
of the cause of stroke is necessary in order to prepare an adequate preventive strategy. In this review
the confirmed and potential causes of embolic strokes are presented, which can be detected in echocardiography in the context of present treatment guidelines and gaps in evidence. There remains a need for further studies assessing the meaning of potential cardiac sources of embolism and establishment of rules for optimal medical prevention (antiplatelet therapy [APT] vs. oral anticoagulation [OAC]) and
interventional procedures to reduce the incidence of ischemic strokes. Currently available data does not provide definitive evidence on the comparative benefits of OAC vs. APT in patients with cryptogenic stroke or embolic stroke of undetermined source. There is a lack of antithrombotic treatment scheme in the time between stroke and the completed diagnosis of potential sources of thromboembolism.

Get Citation

Keywords

cardioembolic stroke; anticoagulant therapy; cardiac sources of embolism; ischemic stroke; cryptogenic stroke

About this article
Title

Established and potential echocardiographic markers of embolism and their therapeutic implications in patients with ischemic stroke

Journal

Cardiology Journal

Issue

Vol 26, No 5 (2019)

Pages

438-450

Published online

2018-04-25

DOI

10.5603/CJ.a2018.0046

Pubmed

29718528

Bibliographic record

Cardiol J 2019;26(5):438-450.

Keywords

cardioembolic stroke
anticoagulant therapy
cardiac sources of embolism
ischemic stroke
cryptogenic stroke

Authors

Paulina E. Gąsiorek
Maciej Banach
Marek Maciejewski
Andrzej Głąbiński
Aleksandra Paduszyńska
Jacek Rysz
Agata Bielecka-Dąbrowa

References (54)
  1. Li X, Zhou G, Zhou X, et al. The efficacy and safety of aspirin plus dipyridamole versus aspirin in secondary prevention following TIA or stroke: a meta-analysis of randomized controlled trials. J Neurol Sci. 2013; 332(1-2): 92–96.
  2. Sacco RL, Kasner SE, Broderick JP, et al. American Heart Association Stroke Council, Council on Cardiovascular Surgery and Anesthesia, Council on Cardiovascular Radiology and Intervention, Council on Cardiovascular and Stroke Nursing, Council on Epidemiology and Prevention, Council on Peripheral Vascular Disease, Council on Nutrition, Physical Activity and Metabolism. An updated definition of stroke for the 21st century: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2013; 44(7): 2064–2089.
  3. Chauhan G, Debette S. Genetic Risk Factors for Ischemic and Hemorrhagic Stroke. Curr Cardiol Reports. 2016; 18(12).
  4. Zhang C, Kasner S. Diagnosis, prognosis, and management of cryptogenic stroke. F1000Res. 2016; 5: 168.
  5. Pepi M, Evangelista A, Nihoyannopoulos P, et al. European Association of Echocardiography. Recommendations for echocardiography use in the diagnosis and management of cardiac sources of embolism: European Association of Echocardiography (EAE) (a registered branch of the ESC). Eur J Echocardiogr. 2010; 11(6): 461–476.
  6. Minematsu K, Yamaguchi T, Omae T. 'Spectacular shrinking deficit': rapid recovery from a major hemispheric syndrome by migration of an embolus. Neurology. 1992; 42(1): 157–162.
  7. Turagam MK, Velagapudi P, Flaker GC. Stroke prevention in the elderly atrial fibrillation patient with comorbid conditions: focus on non-vitamin K antagonist oral anticoagulants. Clin Interv Aging. 2015; 10: 1431–1444.
  8. Hart RG, Diener HC, Coutts SB, et al. Cryptogenic Stroke/ESUS International Working Group. Embolic strokes of undetermined source: the case for a new clinical construct. Lancet Neurol. 2014; 13(4): 429–438.
  9. Papavasileiou V, Milionis H, Michel P, et al. ASTRAL score predicts 5-year dependence and mortality in acute ischemic stroke. Stroke. 2013; 44(6): 1616–1620.
  10. Leithäuser B, Park JW. Cardioembolic stroke in atrial fibrillation-rationale for preventive closure of the left atrial appendage. Korean Circ J. 2009; 39(11): 443–458.
  11. Nakanishi K, Homma S. Role of echocardiography in patients with stroke. J Cardiol. 2016; 68(2): 91–99.
  12. Christiansen CB, Gerds TA, Olesen JB, et al. Atrial fibrillation and risk of stroke: a nationwide cohort study. Europace. 2016; 18(11): 1689–1697.
  13. Dalen JE, Alpert JS. Silent atrial fibrillation and cryptogenic strokes. Am J Med. 2017; 130(3): 264–267.
  14. Olsen FJ, Pedersen S, Jensen JS, et al. Global longitudinal strain predicts incident atrial fibrillation and stroke occurrence after acute myocardial infarction. Medicine (Baltimore). 2016; 95(44): e5338.
  15. Lee AY. Cancer and thromboembolic disease: pathogenic mechanisms. Cancer Treat Rev. 2002; 28(3): 137–140.
  16. Stöllberger C, Wegner C, Finsterer J. CHADS2- and CHA2DS2VASc scores and embolic risk in left ventricular hypertrabeculation/noncompaction. J Stroke Cerebrovasc Dis. 2013; 22(6): 709–712.
  17. Wigger O, Windecker S, Bloechlinger S. Nonbacterial thrombotic endocarditis presenting as intracerebral hemorrhage. Wien Klin Wochenschr. 2016; 128(23-24): 922–924.
  18. Gundersen H, Moynihan B. An Uncommon Cause of Stroke: Non-bacterial Thrombotic Endocarditis. Journal of Stroke and Cerebrovascular Diseases. 2016; 25(10): e163–e164.
  19. Bjessmo S, Ivert T. Cardiac myxoma: 40 years' experience in 63 patients. Ann Thorac Surg. 1997; 63(3): 697–700.
  20. Akdemir I, Dagdelen S, Yuce M, et al. Silent brain infarction in patients with rheumatic mitral stenosis. Jpn Heart J. 2002; 43(2): 137–144.
  21. González A, Altieri P, Màrquez E, et al. Massive pulmonary embolism associated with a right ventricular myxoma. Am J Med. 1980; 69(5): 795–798.
  22. Mattioli AV, Aquilina M, Oldani A, et al. Atrial septal aneurysm as a cardioembolic source in adult patients with stroke and normal carotid arteries. A multicentre study. Eur Heart J. 2001; 22(3): 261–268.
  23. Ihsen Z, Hela M, Khadija M, et al. Cerebral embolism complicating left atrial myxoma: a case report. Pan Afr Med J. 2016; 24: 140.
  24. Merkler AE, Chu SY, Lerario MP, et al. Temporal relationship between infective endocarditis and stroke. Neurology. 2015; 85(6): 512–516.
  25. Zhang F, Zhu Z, Upadhya GK, et al. Papillary fibroelastoma of the aortic valve presenting with chronic angina and acute stroke: a case report. J Med Case Rep. 2017; 11(1): 17.
  26. Krishnan SC, Salazar M. Septal pouch in the left atrium: a new anatomical entity with potential for embolic complications. JACC Cardiovasc Interv. 2010; 3(1): 98–104.
  27. Li L, Yiin GS, Geraghty OC, et al. Oxford Vascular Study. Incidence, outcome, risk factors, and long-term prognosis of cryptogenic transient ischaemic attack and ischaemic stroke: a population-based study. Lancet Neurol. 2015; 14(9): 903–913.
  28. Akhtar J, Wasay M, Rauf J. Atrial myxoma: a rare cause of cardioembolic stroke. BMJ Case Rep. 2012; 2012.
  29. Kraywinkel K, Jauss M, Diener HC, et al. [Patent foramen ovale, atrial septum aneurysm, and stroke. An examination of the status of recent evidence]. Nervenarzt. 2005; 76(8): 935–942.
  30. Rao PA, Nagendra Prakash SN, Vasudev S, et al. A rare case of right ventricular myxoma causing recurrent stroke. Indian Heart J. 2016; 68 Suppl 2: S97–S101.
  31. Sun JP, Meng F, Yang XS, et al. Prevalence of atrial septal pouch and risk of ischemic stroke. Int J Cardiol. 2016; 214: 37–40.
  32. Homma S, Messé SR, Rundek T, et al. Patent foramen ovale. Nat Rev Dis Primers. 2016; 2: 15086.
  33. Tugcu A, Okajima K, Jin Z, et al. Septal pouch in the left atrium and risk of ischemic stroke. JACC Cardiovasc Imaging. 2010; 3(12): 1276–1283.
  34. Wayangankar SA, Patel JH, Patel B, et al. Clinical and echocardiographic variables associated with LA septal pouch. JACC Cardiovasc Imaging. 2013; 6(7): 833–835.
  35. Wong JM, Lombardo DM, Barseghian A, et al. Left atrial septal pouch in cryptogenic stroke. Front Neurol. 2015; 6: 57.
  36. Schuchlenz HW, Saurer G, Weihs W, et al. Persisting eustachian valve in adults: relation to patent foramen ovale and cerebrovascular events. J Am Soc Echocardiogr. 2004; 17(3): 231–233.
  37. Vale TA, Newton JD, Orchard E, et al. Prominence of the Eustachian valve in paradoxical embolism. Eur J Echocardiogr. 2011; 12(1): 33–36.
  38. Jansirani DD, Deep SS, Anandaraja S. Anatomical study of Chiari network and the remnant of left venous valve in the interior of right atrium. Anat Res Int. 2015; 2015: 247680.
  39. Rigatelli G, Dell'avvocata F, Cardaioli P, et al. Migraine-patent foramen ovale connection: role of prominent eustachian valve and large Chiari network in migrainous patients. Am J Med Sci. 2008; 336(6): 458–461.
  40. Overvad TF, Nielsen PB, Larsen TB, et al. Left atrial size and risk of stroke in patients in sinus rhythm. A systematic review. Thromb Haemost. 2016; 116(2): 206–219.
  41. Yaghi S, Chang AD, Hung P, et al. Left Atrial Appendage Morphology and Embolic Stroke of Undetermined Source: A Cross-Sectional Multicenter Pilot Study. J Stroke Cerebrovasc Dis. 2018; 27(6): 1497–1501.
  42. Nouh A, Hussain M, Mehta T, et al. Embolic strokes of unknown source and cryptogenic stroke: implications in clinical practice. Front Neurol. 2016; 7: 37.
  43. Homma S, Sacco RL, Di Tullio MR, et al. PFO in Cryptogenic Stroke Study (PICSS) Investigators. Effect of medical treatment in stroke patients with patent foramen ovale: patent foramen ovale in Cryptogenic Stroke Study. Circulation. 2002; 105(22): 2625–2631.
  44. Biteker M, Kayataş K, Başaran Ö, et al. The role of left atrial volume index in patients with a first-ever acute ischemic stroke. J Stroke Cerebrovasc Dis. 2017; 26(2): 321–326.
  45. Rigatelli G, Aggio S, Cardaioli P, et al. Left atrial dysfunction in patients with patent foramen ovale and atrial septal aneurysm: an alternative concurrent mechanism for arterial embolism? JACC Cardiovasc Interv. 2009; 2(7): 655–662.
  46. Hoit BD. Left atrial size and function: role in prognosis. J Am Coll Cardiol. 2014; 63(6): 493–505.
  47. Mehrpour M, Mehrpour M. Is the serum ferritin level a considerable predictor for hemorrhagic transformation of ischemic stroke? Med J Islam Repub Iran. 2016; 30: 363.
  48. Meier B, Kalesan B, Mattle HP, et al. PC Trial Investigators. Percutaneous closure of patent foramen ovale in cryptogenic embolism. N Engl J Med. 2013; 368(12): 1083–1091.
  49. Wolfrum M, Froehlich GM, Knapp G, et al. Stroke prevention by percutaneous closure of patent foramen ovale: a systematic review and meta-analysis. Heart. 2014; 100(5): 389–395.
  50. Dalen JE, Alpert JS. Cryptogenic strokes and patent foramen ovales: what's the right treatment? Am J Med. 2016; 129(11): 1159–1162.
  51. Wong JM, Fisher M. The potential role of the left atrial septal pouch in cryptogenic stroke. Expert Rev Cardiovasc Ther. 2016; 14(1): 1–3.
  52. Hart RG, Sharma M, Mundl H, et al. Rivaroxaban for secondary stroke prevention in patients with embolic strokes of undetermined source: Design of the NAVIGATE ESUS randomized trial. Eur Stroke J. 2016; 1(3): 146–154.
  53. Geisler T, Poli S, Meisner C, et al. Apixaban for treatment of embolic stroke of undetermined source (ATTICUS randomized trial): Rationale and study design. Int J Stroke. 2017; 12(9): 985–990.
  54. Glass TA, Hennessey PM, Pazdera L, et al. Outcome at 30 days in the New England Medical Center Posterior Circulation Registry. Arch Neurol. 2002; 59(3): 369–376.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl